Performing pharmacokinetic analysis in the pelvic region is very challenging due to high physiological uptake in adjacent structures, high physiological bowel and bladder movements, especially when lesions are small in size after NACT, and unexpected low uptake of the tracer by immunohistochemically confirmed FRα-positive tumor lesions. This evidence concerns the gene FOLR1 and neoplasm.